Cetera Investment Advisers
DAWN

Cetera Investment Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History

Cetera Investment Advisers’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,000
Closed -$326K – 4849
2025
Q4 		$326K Sell
35,000
-4,550
-12% -$38K ﹤0.01% 3830
2025
Q3 		$279K Buy
39,550
+15,850
+67% +$109K ﹤0.01% 3891
2025
Q2 		$154K Sell
23,700
-3,300
-12% -$22.7K ﹤0.01% 3793
2025
Q1 		$214K Sell
27,000
-4,571
-14% -$49.2K ﹤0.01% 3553
2024
Q4 		$400K Buy
31,571
+9,756
+45% +$136K ﹤0.01% 2869
2024
Q3 		$304K Sell
21,815
-4,014
-16% -$57.3K ﹤0.01% 3054
2024
Q2 		$356K Sell
25,829
-1,336
-5% -$19.5K ﹤0.01% 2883
2024
Q1 		$449K Buy
+27,165
New +$407K ﹤0.01% 2682

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Cetera Investment Advisers's DAWN Position: Q1 2026 in Review

Cetera Investment Advisers sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 35,000 shares — an estimated $326K sold.

Cetera Investment Advisers first reported a position in DAWN in Q1 2024 and held it in 8 quarters. The position peaked at $449K in Q1 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Cetera Investment Advisers reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 35,000 Day One Biopharmaceuticals shares in Q1 2026, an estimated $326K.
  • Cetera Investment Advisers first reported a position in Day One Biopharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Cetera Investment Advisers's Day One Biopharmaceuticals position peaked at $449K in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.